Intravenous administration of epinephrine to patients with coronary artery disease may lead to complications ranging from difficulty in breathing to a heart attack. These complications may occur more frequently among patients also taking levothyroxine. Therefore, careful observation is needed when intravenous epinephrine is given to patients receiving levothyroxine who also have coronary artery disease.
Converting a state of hypothyroidism (under activity) to a normal state (euthyroid state) with levothyroxine may decrease the actions of certain beta-blocking drugs, (for example, metoprolol [Lopressor] or propranolol [Inderal]). It may be necessary, therefore, to change the dose of beta-blocker. For the same reason, the dose of digoxin (Lanoxin), a drug used to manage heart failure or an irregular heart rhythm (for example, atrial fibrillation), also may need to be changed.
Taking levothyroxine at the same time as calcium carbonate, ferrous sulphate, cholestyramine (Questran) or colestipol (Colestid) may decrease the effect of levothyroxine and lead to hypothyroidism. This occurs because the levothyroxine binds to these drugs and is not absorbed. Taking the levothyroxine one hour before or four hours after these drugs is necessary to prevent binding.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.